Mayne Pharma Group |
High $4.46 |
Low $4.23 |
Trades 1,020 |
Turnover $2,463,536 |
Volume 565,229 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $277,610,112 (439th) |
Close (30-Jun) $4.40 |
Volume (30-Jun) 565,229 |
Shortsold (6-Nov) 1,890,557 (2.31%) (155th) |
|
52w High $6.04 |
52w Low $2.04 |
P/E 263.16 |
EPS 0.31 |
Initial Director's Interest Notice
MYX released this announcement to the ASX on 5 October 2021, 11:00. The announcement is not marked as price sensitive, and is 2 page(s) in length and 141.52kb in size.
You can view all announcements from MYX and see how they appear on a price chart on the announcements page.
At the date of this announcement, MYX was 1.032% short sold according to ASIC data. It was ranked the 162nd most shorted stock on the ASX. It is now ranked as the 155th most shorted stock on the ASX with 2.309% of total shares short sold as of the latest reported data (06 November 2026).
| Other Recent Announcements from MYX | |
|---|---|
| Notification of cessation of securities - MYX | 30 June 2023, 16:11 |
| Update - Notification of buy-back - MYX | 30 June 2023, 8:19 |
| Update - Notification of buy-back - MYX | 29 June 2023, 8:20 |
| Initial Director's Interest Notice | 5 October 2021, 11:00 |
| Final Director's Interest Notice (x2) | 4 October 2021, 9:35 |
| Mayne Pharma appoints new Director | 4 October 2021, 9:20 |
| Mayne Pharma adds generic ABSORICA to US portfolio | 29 September 2021, 8:25 |
If you were already registered, log in here.